Entering text into the input field will update the search result below

Enrollment underway in study of Dynavax's HEPLISAV-B in renal disease patients

  • The first participant has been enrolled in a 100-subject, open-label, single-arm Phase 1 clinical trial evaluating Dynavax's (NASDAQ:DVAX) HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] in adults with end-stage renal disease who are initiating or are undergoing hemodialysis.
  • The primary endpoints are safety and immunogenicity at week 20 as measured by seroprotection rate.
  • The estimated primary completion date is December.

Recommended For You

About DVAX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
DVAX--
Dynavax Technologies Corporation